scholarly journals The Relationship of Metabolic Syndrome With Disease Activity and the Functional Status in Patients With Rheumatoid Arthritis

Author(s):  
Karakoc
Rheumatology ◽  
1984 ◽  
Vol 23 (1) ◽  
pp. 15-19 ◽  
Author(s):  
J. G. LARKIN ◽  
G. D. O. LOWE ◽  
R. D. STURROCK ◽  
C. D. FORBES

2017 ◽  
Vol 11 ◽  
pp. S425-S427
Author(s):  
Samy Slimani ◽  
Abdelmalek Abbas ◽  
Amina Ben Ammar ◽  
Fadia Rahal ◽  
Imene Khider ◽  
...  

2011 ◽  
Vol 11 ◽  
pp. 1195-1205 ◽  
Author(s):  
Maryam Sahebari ◽  
Ladan Goshayeshi ◽  
Zahra Mirfeizi ◽  
Zahra Rezaieyazdi ◽  
Mohammad R. Hatef ◽  
...  

Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis. Increased prevalence of metabolic syndrome (MetS) in RA may occur secondary to specific drug treatment and reduced physical activity associated with this condition. However, some recent studies suggest contradictory theories about the association of RA with MetS. This study was designed to evaluate the frequency of MetS in RA patients and the relationship between MetS with RA disease activity and body mass index (BMI). The study was conducted on 120 RA patients and 431 age- and sex-matched apparently healthy controls. A considerable proportion of patients were being treated with prednisolone and/or methotrexate and/or hydroxychloroquine. Disease activity was measured by the 28 joint count of disease activity score-Cerythrocyte sedimentation rate (DAS28ESR). MetS was evaluated according to International Diabetic Federation (IDF) and Adult Treatment Panel III (ATP III) criteria. The prevalence of MetS was significantly higher in the control group (p= 0.005). We did not find any difference in the prevalence of MetS between the patients with DAS < 3.2 and DAS ≥ 3.2. There was no association between the DAS28 score and the presence of MetS components by either definition. Multiple logistic regression analysis showed that the odds of a DAS > 3.2 in patients with BMI between 25 and 30 kg/m2(OR = 0.1,p= 0.01) and BMI > 30 kg/m2(OR = 0.3,p= 0.1), in comparison to BMI < 25 kg/m2, was 1/5 and 1/3, respectively. RA was not found to increase the risk of MetS. In addition, disease activity in RA patients was not influenced by the presence of MetS.


Medicina ◽  
2020 ◽  
Vol 56 (10) ◽  
pp. 545
Author(s):  
Khai-Jing Ng ◽  
Hui-Chun Yu ◽  
Hsien-Yu Huang Tseng ◽  
Chia-Wen Hsu ◽  
Ming-Chi Lu

Background and objectives: To investigate the serum procalcitonin (PCT) levels among patients with rheumatoid arthritis (RA) without active infection compared with healthy controls and to understand the relationship of PCT with RA disease activity, and treatment received by patients. Materials and Methods: Patients aged 20 years and above with clinician-confirmed diagnosis of RA and healthy volunteers were included during regular outpatient visits, and those with active infection symptoms and signs were excluded. RA disease activity was measured using the Disease Activity Score-28 for Rheumatoid Arthritis with erythrocyte sedimentation rate (DAS28-ESR). Medications received by the patients were also recorded. Results: A total of 623 patients with RA and 87 healthy subjects were recruited in this study. The mean PCT were significantly higher in patients with RA (6.90 ± 11.81 × 10−3 ng/mL) compared with healthy controls (1.70 ± 6.12 × 10−3 ng/mL) (p < 0.001) and the difference remained statistically significant after adjusting for age and sex. In addition, multiple linear regression analysis showed that a lower rank-transformed PCT serum level was significantly correlated with the use of biologics (p = 0.017) and a high DAS28-ESR score (p = 0.028) in patients with RA. Conclusion: Patients with RA have a significantly higher serum PCT levels compared with healthy controls. The use of biologics and an active RA disease activity were associated with a lower level of PCT in patients with RA. Further investigation is required to determine the optimal cutoff value of PCT among patients with RA and its association with disease activity and biologic usage.


2016 ◽  
Vol 26 (03) ◽  
pp. 165-169 ◽  
Author(s):  
Nidhi Garg ◽  
Ashit Syngle ◽  
Pawan Krishan

AbstractNitric oxide (NO) plays an important role in inflammatory joint disease and endothelial function. Endothelial dysfunction has been attributed to a reduction in NO bioactivity in rheumatoid arthritis (RA). However, the relationship of NO with inflammation and endothelial dysfunction in RA has not yet been investigated.To investigate the relationship of nitrite with inflammation and endothelial dysfunction in RA.Total 28 patients satisfying 2010 Rheumatoid Arthritis Classification Criteria were recruited for the study. Serum nitrite estimation was performed by Griess reaction. Flow-mediated dilation (FMD) assessed using AngioDefender. Inflammatory disease activity measures included disease activity score of 28 joints (DAS28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Proinflammatory cytokines (TNF-α, IL-6, and IL-1) measured using standard ELISA kits. Twenty-five healthy controls matched for age and sex were included for comparison.The serum nitrite level in patients with RA was markedly elevated as compared with controls (p < 0.05). FMD was significantly impaired in RA patients than controls (p < 0.05). DAS28 was significantly higher in RA patients (p < 0.05). Levels of ESR, CRP, TNF-α, IL-1, and IL-6 were significantly higher in RA patients than controls (p < 0.05). Significant positive correlation was observed between nitrite and CRP (r = 0.46, p < 0.05), TNF-α (r = 0.53, p < 0.05), and inverse correlation with FMD (r =0.62, p < 0.05).Inflammatory disease activity and endothelial dysfunction in RA are associated with increased concentration of proinflammatory cytokines and NO. Inflammatory triggered release of cytokines induced NO production that mediates endothelial dysfunction. These findings suggest a role for NO in inflammation-induced endothelial dysfunction in RA.


Sign in / Sign up

Export Citation Format

Share Document